Brind.

Antonio Gracias's company is seeking FDA approval for MDMA, moving its HQ to Chicago, and endowing a Harvard program.

1 report, 1 independent Updated Sep 1

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Antonio Gracias FDA Harvard

Keep exploring

The entities involved

Antonio Gracias
Businessperson and board member, Chief Investment Officer of Valor and Aspen Institute Trustee

Nothing else this week.
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Harvard
city in McHenry County, Illinois, United States

Nothing else this week.

Coverage

Newest first; wire copies grouped

Sep 1livemint.com